Elanco Animal Health Incorporated ELAN
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About ELAN
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Elanco Animal Health Incorporated is a global animal health company focused on developing, manufacturing, and marketing products for companion animals and livestock. The company operates within the broader animal health and veterinary pharmaceutical industries, with revenue primarily generated through pet health therapeutics, parasiticides, vaccines, medicated feed additives, and productivity products for cattle, poultry, swine, and aquaculture markets. Elanco serves veterinarians, livestock producers, retailers, distributors, and pet owners across developed and emerging markets. The company’s portfolio includes products addressing flea and tick control, pain management, dermatology, vaccines, digestive health, and food animal productivity.
Elanco was originally established as the animal health division of Eli Lilly and Company before being separated through an initial public offering in 2018 and fully spun off in 2019. The company significantly expanded its scale through the acquisition of Bayer Animal Health in 2020, which strengthened its companion animal portfolio and broadened its international presence. Elanco’s strategic positioning is built around a diversified product base spanning both pet health and farm animal health, extensive veterinary relationships, and global distribution capabilities.
Business Operations
Elanco organizes its operations primarily around two major business categories: Pet Health and Farm Animal. The Pet Health business includes products for parasiticides, vaccines, therapeutics, and animal wellness solutions for dogs and cats, with major brands including Credelio, Advantage, Seresto, and Galliprant. The Farm Animal segment includes products for cattle, poultry, swine, and aquatic species, supporting disease prevention, feed efficiency, and productivity. Revenue is generated through direct product sales, veterinary distribution channels, agricultural supply networks, and retail partnerships.
The company operates manufacturing, research, and commercial facilities across North America, Europe, Latin America, and Asia-Pacific. Elanco controls a broad portfolio of intellectual property, regulatory approvals, biologics capabilities, and manufacturing assets. Important subsidiaries and acquired operations include Bayer Animal Health, which remains central to Elanco’s companion animal strategy. The company also maintains partnerships with veterinary clinics, livestock producers, and distributors globally. Public filings and investor disclosures consistently identify product innovation, lifecycle management, and operational integration as central operational priorities.
Strategic Position & Investments
Elanco’s strategic direction has focused on strengthening its companion animal business while maintaining a significant livestock health platform. Following the acquisition of Bayer Animal Health, the company emphasized portfolio integration, debt reduction, operational efficiency, and targeted innovation in parasiticides, vaccines, and pet therapeutics. Elanco has also invested in digital livestock technologies, sustainability-oriented animal production solutions, and expanded biologics capabilities intended to improve disease prevention and productivity outcomes.
The company has pursued selective divestitures and portfolio optimization initiatives to streamline operations and improve margins. Elanco continues to invest in research and development targeting chronic pet conditions, veterinary therapeutics, and alternatives aligned with evolving regulatory standards in food animal production. Management has publicly identified companion animal health, global protein demand, and data-driven livestock management as long-term growth drivers. Information regarding certain pipeline programs and emerging technologies remains limited to company disclosures, and some forward-looking commercial impacts are inconclusive based on available public sources.
Geographic Footprint
Elanco is headquartered in Greenfield, Indiana, United States, and operates in more than 90 countries. The company maintains a substantial presence across North America, Europe, Latin America, and Asia-Pacific, supported by regional manufacturing, research, supply chain, and commercial infrastructure. The acquisition of Bayer Animal Health materially expanded Elanco’s international distribution network and strengthened its market access in Europe and emerging markets.
The company’s products are sold globally through veterinary clinics, agricultural distributors, retail channels, and direct commercial relationships. Elanco has operational influence in major livestock-producing regions including the United States, Brazil, China, and parts of Europe, while also maintaining strong exposure to companion animal markets in developed economies. Its international operations are supported by region-specific regulatory approvals, local commercial teams, and manufacturing capabilities distributed across multiple continents.
Leadership & Governance
Elanco’s leadership structure combines pharmaceutical, agricultural, and consumer health experience. The company’s governance framework is overseen by a board of directors and executive leadership team responsible for commercial execution, innovation, regulatory compliance, and capital allocation. Since becoming an independent public company, leadership has emphasized operational discipline, innovation in animal health, and integration of acquired businesses to drive long-term growth.
Key executives include:
- Jeffrey N. Simmons – President and Chief Executive Officer
- Todd Young – Executive Vice President and Chief Financial Officer
- José Manuel Alba – Executive Vice President, Global Manufacturing and Quality
- Michael J. Smith – Executive Vice President, U.S. Pet Health and Global Digital Transformation
- Rajeev Anand – Executive Vice President, Innovation and Regulatory Affairs
- Karen Pfeiffer – Executive Vice President, Corporate Strategy and Business Development
Leadership communications in annual reports and investor presentations consistently emphasize innovation, customer-centric product development, operational efficiency, and strengthening Elanco’s position in both companion animal and livestock health markets.